Related Experiment Video

Updated: Aug 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Angiotensin II-receptor antagonist in the treatment of hypertension

Massimo Volpe1, Giuliano Tocci, Erika Pagannone

  • 1Division of Cardiology, II Faculty of Medicine, University of Rome La Sapienza, Ospedale Sant'Andrea, Via di Grottarossa, 1035-39, 00189 Rome, Italy. volpema@uniroma1.it

Current Hypertension Reports
|August 3, 2005
PubMed

Insights

Effective treatment of high blood pressure is key to reducing cardiovascular risk. Angiotensin II-receptor blockers (ARBs) offer significant benefits in preventing cardiovascular and renal diseases, extending beyond blood pressure control.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hypertension management is critical for reducing global cardiovascular risk.
  • Intensive blood pressure lowering significantly reduces cardiovascular and renal morbidity and mortality.
  • Factors beyond blood pressure control are important in mitigating hypertension-related risks.

Purpose of the Study:

  • To evaluate the role of angiotensin II-receptor blockers (ARBs) in cardiovascular and renal disease prevention.
  • To present evidence supporting ARBs' benefits beyond blood pressure reduction.
  • To highlight ARBs as a key therapeutic option in hypertension management.

Main Methods:

  • Review of evidence from large, international, randomized trials on ARBs.
  • Analysis of clinical benefits of ARBs across varying disease severities.
  • Assessment of ARBs' impact on primary and secondary prevention.

Main Results:

  • ARBs have demonstrated significant clinical benefits in numerous trials.
  • Evidence supports ARBs' efficacy in both primary and secondary prevention.
  • ARBs play a role in cardiovascular and renal protection independent of blood pressure lowering.

Conclusions:

  • Angiotensin II-receptor blockers (ARBs) are a valuable addition to hypertension treatment.
  • ARBs provide cardiovascular and renal protection beyond their antihypertensive effects.
  • Further research supports the use of ARBs for comprehensive risk reduction in hypertensive patients.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...